1
Clinical Trials associated with CD19-targeted CART cells(The First Hospital of Jilin University) / Unknown statusPhase 1IIT Safety and Clinical Activity of CD19 Chimeric Antigen Receptor T Cells in Treating Patients With Recurrent or Refractory CD19 Positive B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic leukemia,and dynamically observe the changes of CAR-T in patients and the residual tumor.
100 Clinical Results associated with CD19-targeted CART cells(The First Hospital of Jilin University)
100 Translational Medicine associated with CD19-targeted CART cells(The First Hospital of Jilin University)
100 Patents (Medical) associated with CD19-targeted CART cells(The First Hospital of Jilin University)
100 Deals associated with CD19-targeted CART cells(The First Hospital of Jilin University)